1 When administered subcutaneously HS-599, a new didehydroderivative of buprenorphine (18,19-dehydrobuprenorphine), produced a long-lasting antinociceptive response in rats. Its potency exceeded twice that of buprenorphine. In the tail-¯ick test it acted as a full agonist but in the plantar test only as a partial agonist. Whereas the m-opioid antagonists naloxone and naltrexone antagonized HS-599 antinociception the d-opioid antagonist naltrindole and the k-opioid antagonist nor-binaltorphimine did not. 2 Unlike buprenorphine and morphine, HS-599 never induced conditioned place-preference in rats. 3 In radioligand binding assays, compared with buprenorphine HS-599 had 3 fold higher m-opioid receptor anity but lower d-and k-opioid receptor anity. 4 In isolated guinea-pig ileum preparations, HS-599 only partially inhibited the electricallystimulated contraction, acting as a partial opioid agonist. When tested against the m-opioid receptor agonist dermorphin, it behaved as a non-equilibrium antagonist. Conversely, in mouse vas deferens (rich in d-opioid receptors) and rabbit vas deferens preparations (rich in k-opioid receptors) HS-599 acted as a pure equilibrium antagonist, shifting the log-concentration-response curves of the d-opioid agonist deltorphin I and the k-opioid agonist U-69593 to the right. 5 In conclusion, HS-599 is a novel buprenorphine derivative with higher anity, selectivity and potency than the parent compound, for m-opioid receptors. It produces intense and long-lasting antinociception and does not induce place-preference in rats.
Introduction
In clinical practice, opioid analgesic drugs are widely used for the relief of severe pain. Unfortunately, their use is limited by their numerous side eects including respiratory depression, constipation and addiction.
In the search for alternative analgesics to morphine, interest has focused on opioids with mixed agonistantagonist pro®les. These compounds commonly exhibit low-to-moderate intrinsic activity at m-receptors. Hence they produce analgesia with only mild side-eects. Buprenorphine is a potent analgesic drug that has demonstrable agonist and antagonist activity (Cowan et al., 1977a, b; Heel et al., 1979) . Whereas buprenorphine is a partial agonist at m-opioid receptors and an antagonist at d-opioid receptors, its role at k-opioid receptors remains less clear (Leander, 1988; Tyers, 1980; Kamei et al., 1995; Pick et al., 1997) . Despite strong evidence that buprenorphine acts as a full antagonist at k receptors (Leander, 1987) , it has k 3 and to a lesser extent k 1 agonistic activity (Pick et al., 1997) . Although buprenorphine is 20 ± 30 times more potent than morphine as an analgesic it induces scarce respiratory depression and is currently indicated as a therapeutic agent with low abuse potential (Pick et al., 1997; Michiteru et al., 1997) . Because of these characteristics, buprenorphine is used as an alternative to methadone in maintenance and detoxi®cation treatment of heroin addicts (Reisinger, 1985; Bickel et al., 1988; Kosten & Kleber, 1988; Diamant et al., 1998) . Nevertheless, reports from various countries have described buprenorphine abuse (O'Connor et al., 1988; Chowdhury & Chowdhury, 1990; San et al., 1993) . Buprenorphine also maintains selfadministration (Mello et al., 1981; Young et al., 1984) and induces place preference in animals (Gaiardi et al., 1997; Brown et al., 1991; Rowlett et al., 1994; Pchelintsev et al., 1991) .
With the aim of developing new and potent analgesics with lower abuse potential than available opiates, we studied the antinociceptive and addicting properties of a derivative of buprenorphine, named HS-599 (Schutz et al., 2001) (Figure  1) , after s.c. administration in rats. We also evaluated the receptor anities and the in vitro biological activity of HS-599 in comparison with those of morphine, buprenorphine, dermorphin (a m-opioid receptor agonist), deltorphin I and II (d-opioid receptor agonists) and U69-593 (a k-opioid receptor agonist). 
Methods

In vitro experiments
Binding assays Binding of HS-599 and buprenorphine to m, d and ORL 1 opioid receptors was assayed on crude membrane preparations from adult male rat brain (Wistar, 250 ± 300 g). Binding to k-opioid receptors was assayed on crude membrane preparations from adult male guinea-pig brain (450 g) as previously described (Melchiorri et al., 1991) . The brains were homogenized in 50 volumes of Tris-HCl buer (50 mM, pH 7.4, 48C) using a Kinematica PT 3000 polytron (20 s, speed 16,000 r.p.m.). The homogenate was centrifuged at 41,0006g for 20 min at 48C, pellets were resuspended in 50 vol of buer and incubated at 258C per 30 min to remove endogenous opioids. After centrifugation, pellets were resuspended in buer, containing 5% glycerol, to give a ®nal w v 71 of 20 mg ml 71 fresh tissue. ). Drugs were assayed on 1 mg brain membrane protein, in a ®nal volume of 2 ml Tris-HCl buer (50 mM, pH 7.4), at 358C for 90 min. All experiments were performed in triplicate and total binding, nonspeci®c binding (10 mM naloxone) and 12 inhibitor concentrations were determined. Reagents and membranes were distributed with a robotic sample processor (Tecan RSP 5000-series). Using a Brandel M-24 cell harvester, assays were terminated by ®ltration through Whatman GF/B ®lter strips previously soaked in 0.5% polyethylenimine for 1 h. Filters were washed three times with 4 ml of ice-cold buer and radioactivity was counted in a liquid scintillation spectrometer (Betamatic, Kontron). The inhibition constant (K i ) of the drugs was calculated from competitive binding curves with the computer program Ligand (Munson & Rodbard, 1980) . Data are presented as the arithmetic mean+s.e.mean of four independent measurements.
Activity on isolated organ preparations Preparations of the myenteric plexus-longitudinal muscle obtained from male guinea-pig ileum (GPI, rich in m-opioid receptors), preparations of mouse vas deferens (MVD, rich in d-opioid receptors) and rabbit vas deferens (RVD, rich in k-opioid receptors) were used for ®eld stimulation with bipolar rectangular pulses of supramaximal voltage (Melchiorri et al., 1991) . Agonists were evaluated for their ability to inhibit the electrically-evoked twitch. The biological potency of HS-599 was compared with that of the m-opioid receptor agonist dermorphin in GPI, with that of the d-opioid receptor agonist deltorphin I in MVD and with that of the k-opioid receptor agonist U-69593 in RVD. Concentration-response curves were analysed with the Prism computer program.
In vivo experiments
Male Wistar rats (250 ± 300 g) were used. All animals were housed at 22+28C, with food and water ad libitum. A standard light/dark cycle was maintained with a timeregulated light period from 0600 h to 1800 h. The IASP guidelines on ethical standards for investigations of experimental pain in animals were followed. Compounds were dissolved in 10% DMSO and administered to the rats in a volume of 0.2 ml kg 71 of body weight (b.w.). Control rats received vehicle at 0.2 ml kg 71 of b.w. Each animal received one injection only. Every dose of each compound was evaluated in groups of 6 ± 8 animals.
Antinociception studies
Analgesia was measured by the tail-¯ick test (D'amour & Smith, 1941) and the plantar test (Hargreaves et al., 1988) . In the tail-¯ick test a radiant heat stimulus is focused on the blackened area of the tail. In the plantar test the plantar surface of the rat's hindpaw is exposed to a beam of radiant heat applied through the glass¯oor of a testing chamber. To escape the nociceptive stimulus, the animal¯icks its tail or briskly withdraws its paw. Each rat served as its own control. Before drug administration, each rat was tested and the latency to tail-¯ick or to paw withdrawal recorded (control latency, CL). The latency to tail-¯ick or to paw withdrawal of each drug-injected rat was de®ned as the test latency (TL). After drug injections, the test was repeated every 15 min during the ®rst hour and then every 30 min until analgesia disappeared. To avoid tissue damage, rats with a test latency higher than 15 s (cut-o time) were removed from the nociceptive stimuli and assigned a TL of 15. For drawing the dose-response and time-response curves, the antinociceptive response was expressed as percentage of maximum possible eect (%MPE), calculated by the following equation: %MPE=1006(TL 7 CL)/(15 7 CL). Doses that produced peak eects between 20 and 80% MPE were plotted into a log dose-response curve and AD 50 values, with 95% con®dence intervals (CI), were calculated as doses that produced an analgesic peak eect equal to 50% MPE (Tallarida & Murray, 1986) . For each dose at least ®ve rats were checked.
Place-preference
The place-preference apparatus consisted of two boxes (18618618 cm): one box had white walls and a smooth white¯oor whereas the other had black-and-white checkered New buprenorphine analogue and place preference R. Lattanzi et alwalls with a wire grid on a black¯oor. A sliding wall connected the two compartments. A 20610 cm corridor with a sliding door allowed the rat to go into the centre of the apparatus. An automated timer measured the time rats spent in each compartment. The experiments took place in a small sound insulated and ventilated room illuminated with red lights. On the ®rst day each rat was free to explore the two compartments for 15 min. On the second day, the time each rat spent in the black and the white compartments was recorded for 15 min. Rats had a slight preference for the black compartment; they spent 402+90 s in the black and 380+65 s in the white compartment. All drug injections were therefore paired with the white compartment. From the third day on six groups of rats (n=6) ). During a typical session, the rat was injected, then placed for 60 min into its training compartment. On the day after training rats were tested. For testing, animals were placed in the central corridor and allowed to explore both compartments for 15 min; the time (seconds) spent on the drug paired side was recorded.
Drugs
Buprenorphine HCl, morphine HCl, naloxone and naltrexone were bought from S.A.L.A.R.S. (Como, Italy). Dermorphin, deltorphin I and deltorphin II were synthesized as previously described (Negri et al., 1992; Erspamer et al., 1989) . Naltrindole was purchased from Sigma (Italy) and norbinaltorphimine was purchased from Tocris, U.K.
The selective m-opioid receptor ligand [ was synthesized as previously described (Schutz et al., 2001) .
Results
Receptor binding and GPI-MVD assay
In radioligand binding assays, performed on crude membrane homogenates, HS-599 displayed m-opioid receptor anity about three times higher than that of buprenorphine but lower d-and k-opioid receptor anities so that m/d and m/k selectivity of HS-599 was about one order of magnitude higher than that of buprenorphine. Neither HS-599 nor buprenorphine displayed any anity for ORL 1 receptors (Table 1) .
On GPI preparations, HS-599 inhibited the electricallyevoked twitch concentration-dependently between 2.1 nM and 4.3 mM. HS-599 twitch inhibition was prevented by naloxone (NLX) 200 nM (data not shown). Concentration-response curves (Figure 2) showed that dermorphin produced 100% inhibition of electrically-stimulated contractions of GPI, whereas buprenorphine produced 70% and HS-599 less than 50% of the maximum eect, displaying a signi®cantly lower ecacy than buprenorphine. HS-599 bound irreversibly to GPI: even prolonged, repeated washing left twitch inhibition unchanged. Because of its irreversible binding, each dose of HS-599 was tested on dierent GPI preparations and compared with dermorphin as an internal standard.
HS-599 acted as a non-equilibrium antagonist of the full agonist dermorphin reducing the slope and maximum of the dermorphin log-concentration-response curve (Figure 3) . On MVD and RVD, at concentrations up to 3.0 mM HS-599 never inhibited the electrically-stimulated contractions. But it shifted the log-concentration-eect curve of deltorphin I on MVD and U-69593 on RVD to the right (Figures 4 and 5) . HS-599 also left the log-concentration-eect slopes of the deltorphin I and U-69593 curves unchanged, indicating that it acted as an equilibrium antagonist of d-and k-opioid receptors. Tail (Figure 8 ). The doses and times used in this study were those known to obtain the best selectivity and antagonist activity in rat.
Antinociception studies
Plantar test In this test HS-599 displayed poor antinociceptive activity: the 0.25 mmol kg 71 s.c. dose elicited the maximum antinociceptive eect, less than 50% MPE. Higher doses (0.8 ± 20 mmol kg 71 s.c.) were always less ecacious. Buprenorphine (0.21 ± 1 mmol kg 71 s.c.) and morphine (12 ± 50 mmol kg 71 s.c.) both produced dose-related antinociception that reached the maximum analgesic eect (Figure 9 ). Pre-treatment with NLX 3 mg kg 71 antagonized the HS-599 (0.25 mmol kg 71 s.c.)-induced increased latency to paw withdrawal (data not shown).
Place-preference
In this test, a standard method for highlighting the rewarding properties of psychoactive, addicting drugs, none of the HS-599 doses tested ± from a sub-analgesic dose (0.003 mmol kg 71 s.c.) to a dose (0.43 mmol kg 71 s.c.) twice as high as that inducing the maximum antinociceptive eect in the tail-¯ick test in rats ± induced preference for the drugpaired compartment in rats (for all tested doses: P5 0.0680). Conversely, at doses corresponding to AD 50 buprenorphine and morphine induced a signi®cant preference, about 80%, for the all-white compartment (buprenorphine, P=0.0021; morphine, P=0.0003) (Figure 10 ).
Discussion
These ®ndings show that like its parent compound, the didehydroderivative of buprenorphine, HS-599 is a potent and long-lasting analgesic in rats. But when tested in the place-conditioning test in rats, unlike buprenorphine, it had no rewarding eects. Our in vitro experiments showed that HS-599 has signi®cantly higher m-opioid receptor anity than buprenorphine. Yet it acted as a partial m-opioid receptor agonist endowed with lower intrinsic activity than buprenorphine. Dissociation from the m-receptors being very slow in GPI preparations it behaved as a non-equilibrium partial antagonist toward the m-opioid receptor agonist dermorphin. It bound to d-and k-opioid receptors acting as a pure antagonist on MVD and on RVD preparations, reversibly blocking the twitch inhibition produced by the d-opioid agonist deltorphin I and by the k-opioid agonist U-69593 respectively.
The in vivo experiments conducted in this study with selective opioid antagonists indicate that HS-599 exerts its antinociceptive activity via m-opioid receptors and exclude participation of d-or k-opioid receptors. Accordingly, the m antagonists, NLX and NLTX, blocked whereas the dselective antagonist, NTI, and the k-selective antagonist, nor-BNI, failed to reverse HS-599 induced analgesia. Moreover, in the tail-¯ick test ± a test involving spinal re¯exes ± HS-599 behaved as a full agonist, but in the plantar test ± a test involving more complex supraspinal neuronal circuits ± analgesia never exceeded 50% MPE. In contrast, at the doses we tested, buprenorphine behaved as a full agonist in both tests. As well as acting as a partial m-agonist, buprenorphine has been proven to elicit analgesia through an interaction with k3receptors (Tyers, 1980; Pick et al., 1997) . Hence the activity of buprenorphine and HS-599 could have diered in the plantar test owing to the k 3 agonistic activity of buprenorphine, insofar as k 3 analgesia is mediated supraspinally (Paul et al., 1990) . Alternatively, owing to its lower intrinsic activity HS-599 was less able than buprenorphine to activate the supraspinal m-opioid receptors.
As a ®rst approach in assessing the potential reinforcing properties of a test substance the conditioned place preference paradigm is a useful tool. Our place-conditioning data are largely consistent with previous reports indicating Figure 6 Dose-response relationship of the antinociception produced by s.c. injection of HS-599, buprenorphine and morphine evaluated with tail-¯ick test in rats. Curves were ®tted to data points and analysed by a linear regression computer program (Tallarida & Murray, 1986 . Each point represents the mean antinociceptive peak eect of 5 ± 8 rats+s.e.mean. Figure 10 Eect of HS-599, buprenorphine and morphine on conditioned place-preference test in rats. Results are presented as mean+s.e.mean of time (seconds) that rats spent in the drug paired compartment before (control) and after the acquisition of conditioned place-preference (n=6 per group). Results were analysed by a paired two-tailed t-test. All HS-599 values P50.0680 (not signi®-cant); buprenorphine, **P=0.0021; morphine, ***P=0.0003. that both s.c. (Gaiardi et al., 1997) and i.p. (Brown et al., 1991; Rowlett et al., 1994) injection of buprenorphine has rewarding eects in rats. Under the same conditions and at the doses we tested, HS-599 never caused place-preference.
It is known that the reinforcing and aversive properties of a drug are considered the main attributes that regulate drugseeking behaviour. In rats, activation of m-opioid receptors has been predominantly associated with reinforcing properties while activation of k-opioid receptors has been associated with aversive properties. Buprenophrine is a m-opioid receptors partial agonist and a k-opioid receptors antagonist with the same anity for m-and k-opioid receptors. As the aversive properties are thought to work against the positive ones, the dissociation of rewarding and aversive eects, observed with buprenorphine, could facilitate drug-seeking behaviour (Gaiardi et al., 1997) . HS-599, thus being a mopioid receptors partial agonist and a k-opioid receptors antagonist like the parent compound, displayed 20 times lower k-anity than m-anity. Hence, unlike buprenorphine, at doses inducing analgesia through activation of m-opioid receptors, HS-599 does reasonably not involve k-opioid receptors. Moreover, to the extent that increased abuse potential is related prevalently to m-opioid receptors activation (Negus et al., 1990; Riley & Pournaghash., 1995) , it is worth noting that HS-599 has signi®cantly lower intrinsic activity than buprenorphine at peripheral (GPI) and supraspinal (plantar test) m-opioid receptors suggesting that such receptor activity produces stimulus eects insucient to establish a biological signal necessary to elicit place conditioning.
In conclusion, the higher m/k selectivity together with lower m-intrinsic activity of HS-599 at supraspinal level with respect to buprenorphine could explain why it does not induce place conditioning in rats. HS-599 could be of value as a substitute for methadone and buprenorphine in the weaned substitutive techniques of the drug addicts.
Moreover, at spinal level HS-599 antinociceptive activity is 50 times higher than that of morphine.
